Fulcrum Therapeutics, Inc. Appoints Josh Lehrer to Board of Directors

Published: 2026-04-27 08:50:22 ET FULC

Published on 04/27/2026 at 08:50 am EDT

Fulcrum Therapeutics, Inc. appointed Josh Lehrer, M.D., M.Phil., FACC, an experienced leader in sickle cell disease drug development, to the Board of Directors. Josh?s track record advancing transformative therapies for patients with sickle cell disease, most notably his experience with the development and approval of Oxbryta®, will be invaluable as company advance pociredir into the next phase of development.